Suspected neurological conditions: recognition and referral (NG127)Product type:GuidanceProgramme:NICE guidelineLast updated: 2 October 2023Published: 1 May 2019
Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 October 2019
Cerebral palsy in adults (NG119)Product type:GuidanceProgramme:NICE guidelinePublished: 15 January 2019
Cerebral palsy in under 25s: assessment and management (NG62)Product type:GuidanceProgramme:NICE guidelinePublished: 25 January 2017
Selective dorsal rhizotomy for spasticity in cerebral palsy (IPG373)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 15 December 2010
The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs (MIB159)Product type:AdviceProgramme:Medtech innovation briefingPublished: 14 September 2018
Mollii suit for spasticity (MIB100)Product type:AdviceProgramme:Medtech innovation briefingPublished: 28 March 2017
Severe sialorrhoea (drooling) in children and young people with chronic neurological disorders: oral glycopyrronium bromide (ES5)Product type:AdviceProgramme:Evidence summaryPublished: 14 February 2017
ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)Product type:AdviceProgramme:Medtech innovation briefingPublished: 11 March 2016
Suspected neurological conditions: recognition and referral (QS198)Product type:Quality standardPublished: 8 January 2021
Cerebral palsy in children and young people (QS162)Product type:Quality standardPublished: 10 October 2017